AIKIDO PHARMA INC (AIKI)       6.23  -0.07 (-1.11%)

6.23  -0.07 (-1.11%)

US0088753043 - Common Stock


Fundamental Rating

We assign a fundamental rating of 4 out of 10 to AIKI. AIKI was compared to 644 industry peers in the Biotechnology industry. While AIKI has a great health rating, but there are worries on its profitability. AIKI is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating


AIKI's Return On Assets of -5.72% is amongst the best returns of the industry. AIKI outperforms 90% of its industry peers. The industry average Return On Assets is -40.38%.
AIKI has negative profitability rations, so we won't be analyzing them here.

AIKI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of AIKI.
VS Industry

ROA (-5.72%) VS Industry: 90% outperformed.

-1,226.49
115.38

Valuation

Valuation Rating


With a price book ratio of 0.28, AIKI is valued rather cheaply.
Compared to an average industry price book ratio of 1.93, AIKI is valued rather cheaply. On top of this, AIKI is cheaper than 98% of the companies listed in the same industry.
The Price/Earnings Ratio is negative for AIKI. In the last year negative earnings were reported.

Also next year AIKI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
When comparing the Enterprise Value to EBITDA ratio of AIKI to the average industry ratio of 0.77, AIKI is valued more expensive than its industry peers.
VS Industry

Price/Book (0.28) VS Industry: 98% outperformed.

669.86
0.07

Enterprise Value/ EBITDA (3.44) VS Industry: 22% outperformed.

4,992.29
0.00

Growth

Growth Rating


Based on estimates for the next 5 years, AIKI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.69% on average per year.

The earnings per share for AIKI have decreased strongly by -596.19% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -596.19% 84.56% 38% 25.87% 14.69%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating


A Current Ratio of 110.82 indicates that AIKI has no problem at all paying its short term obligations.
The Current Ratio of AIKI is much better than the industry average of 6.69. AIKI has a better rating than 99% of its industry peers.
A Quick Ratio of 110.82 indicates that AIKI has no problem at all paying its short term obligations.
AIKI is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.55. AIKI has a better rating than 99% of its industry peers.

AIKI has an Altman-Z score of 20.37. This indicates that AIKI is financially healthy and little risk of bankruptcy at the moment.
AIKI has one of the better Altman-Z scores in its industry. It is much better than the industry average of 0.49. AIKI has a better score than 91% of its industry peers.
The Debt to Equity ratio of AIKI is in line with the industry averages.
The Piotroski-F score of AIKI is 3.00. This is a low score and indicates issues in the health and profitability of AIKI.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

18.24
0.00

Quick Ratio (110.82) VS Industry: 99% outperformed.

0.04
138.86

Current Ratio (110.82) VS Industry: 99% outperformed.

0.15
140.77

Altman-Z (20.37) VS Industry: 91% outperformed.

-253.58
1,332.86

Dividend

Dividend Rating


AIKI does not give a dividend.

AIKI Daily chart

AIKIDO PHARMA INC6.23

NASDAQ:AIKI (8/16/2022, 7:15:40 PM)-0.07 (-1.11%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 05-16 2022-05-16/dmh Earnings (Next) 08-23 2022-08-23/amc
Ins Owners 6.19% Inst Owners 13.66%
Market Cap 32.72M Analysts 82.86
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.28
EV/EBITDA 3.44
Profitability
ROA -5.72% ROE N/A
PM N/A Asset Turnover N/A
Growth
EPS 1Y -596.19% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -871.43%
EPS Next Y 84.56% EPS Next 2Y 38%
EPS Next 3Y 25.87% EPS Next 5Y 14.69%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 110.82 Quick Ratio 110.82
Altman-Z 20.37 F-Score 3
Debt/Equity 0
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA